John G.  McHutchison net worth and biography

John McHutchison Biography and Net Worth

Dr. McHutchison joined Assembly as Chief Executive Officer and President in 2019 and was also appointed as a Director. He most recently served as Chief Scientific Officer and Head of Research and Development at Gilead Sciences. During his nine years at Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas including the curative treatment regimens for chronic hepatitis C (HCV), and treatment of chronic HBV. Prior to Gilead, Dr. McHutchison held numerous positions at Duke University Medical Center, including Associate Director of the Duke Clinical Research Institute, Professor of Medicine in the Division of Gastroenterology, Director at Duke Clinical Research Unit and Co-Director of the Duke Clinical and Translational Science Award. Earlier in his career, Dr. McHutchison spent nearly a decade at Scripps Clinic and Research Foundation, and was previously an Assistant Professor of Medicine at the University of Southern California in Los Angeles. Dr. McHutchison received his degrees in medicine and surgery from the University of Melbourne in Australia, completed an internal medicine residency and gastroenterology fellowship at the Royal Melbourne Hospital, and a post-doctoral fellowship in Liver Diseases at the University of Southern California. He is a member of the Royal Australasian College of Physicians, and in 2018, he was appointed an Officer of the Order of Australia (AO).

What is John G. McHutchison's net worth?

The estimated net worth of John G. McHutchison is at least $317,317.44 as of May 23rd, 2024. Dr. McHutchison owns 19,104 shares of Assembly Biosciences stock worth more than $317,317 as of December 3rd. This net worth estimate does not reflect any other investments that Dr. McHutchison may own. Learn More about John G. McHutchison's net worth.

How do I contact John G. McHutchison?

The corporate mailing address for Dr. McHutchison and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on John G. McHutchison's contact information.

Has John G. McHutchison been buying or selling shares of Assembly Biosciences?

John G. McHutchison has not been actively trading shares of Assembly Biosciences in the last ninety days. Most recently, John G. Mchutchison sold 2,117 shares of the business's stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $14.93, for a transaction totalling $31,606.81. Following the completion of the sale, the director now directly owns 19,104 shares of the company's stock, valued at $285,222.72. Learn More on John G. McHutchison's trading history.

Who are Assembly Biosciences' active insiders?

Assembly Biosciences' insider roster includes William Delaney (Insider), John McHutchison (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.

Are insiders buying or selling shares of Assembly Biosciences?

During the last twelve months, Assembly Biosciences insiders bought shares 4 times. They purchased a total of 43,999 shares worth more than $491,421.38. During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 7,974 shares worth more than $108,873.30. The most recent insider tranaction occured on November, 18th when insider Nicole S White sold 40 shares worth more than $651.60. Insiders at Assembly Biosciences own 5.1% of the company. Learn More about insider trades at Assembly Biosciences.

Information on this page was last updated on 11/18/2024.

John G. McHutchison Insider Trading History at Assembly Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2024Sell2,117$14.93$31,606.8119,104View SEC Filing Icon  
4/1/2024Sell1,206$13.07$15,762.4221,221View SEC Filing Icon  
5/23/2023Sell2,164$12.48$27,006.7214,096View SEC Filing Icon  
3/30/2023Sell1,240$9.84$12,201.6014,802View SEC Filing Icon  
8/8/2022Sell1,026$25.56$26,224.5616,042View SEC Filing Icon  
3/30/2022Sell384$26.04$9,999.36View SEC Filing Icon  
8/9/2021Sell1,013$43.20$43,761.60View SEC Filing Icon  
See Full Table

John G. McHutchison Buying and Selling Activity at Assembly Biosciences

This chart shows John G Mchutchison's buying and selling at Assembly Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Assembly Biosciences Company Overview

Assembly Biosciences logo
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $16.62
Low: $16.00
High: $16.99

50 Day Range

MA: $16.29
Low: $14.42
High: $18.52

2 Week Range

Now: $16.62
Low: $8.43
High: $19.93

Volume

24,399 shs

Average Volume

24,161 shs

Market Capitalization

$105.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59